23:00:44 Europe / Stockholm

Prenumeration

2023-08-30 13:51:00

Redeye comments on Fluoguide’s Q2 2023 report as top-line data from the company’s phase IIb trial in high-grade glioma are just around the corner in Q4 2023e. We judge that positive phase IIb HGG and phase IIa HNSCC data are critical to FG001’s clinical development, associated funding, and attracting potential partners.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/